DARZALEX:

used to treat multiple myeloma, a type of blood cancer

Slows or stops cancer progression:

DARZALEX helps to slow or stop the growth and spread of myeloma cells. 

• Increases progression-free survival:

  Clinical trials have shown that DARZALEX, when used in combination with other therapies, can significantly increase the time patients live without their cancer worsening or recurring. 

• Deep responses and MRD negativity:

  DARZALEX-based regimens have been shown to lead to deep responses and high rates of minimal residual disease (MRD) negativity, meaning that a very sensitive test cannot detect any myeloma cells in the bone marrow.